Payment overview · 2025
General Payments
$3,342.01
222 reported records · 36 companies
Healthcare provider profile · identity verified
David E Schultz, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EVANSVILLE, IN · NPI 1912987363
Verified facts
What the public records show
CMS Open Payments records show David E Schultz, M.D. received $3,342.01 in general payments during 2025 across 222 reported records.
ABBVIE INC. accounted for 14.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 58 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Entresto, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Trintellix, Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 477 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Rexulti by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 477 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $498.65 | 14.9% | 36 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $234.72 | 7.0% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $225.29 | 6.7% | 19 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $202.76 | 6.1% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.75 | 5.2% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $172.37 | 5.2% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $156.43 | 4.7% | 13 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $155.28 | 4.7% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $153.74 | 4.6% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $145.34 | 4.3% | 12 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $137.11 | 4.1% | 19 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $135.97 | 4.1% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $85.08 | 2.5% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $76.90 | 2.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $72.30 | 2.2% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $66.60 | 2.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $65.64 | 2.0% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.12 | 1.9% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $63.22 | 1.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $56.96 | 1.7% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.56 | 1.6% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $47.99 | 1.4% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$34.77 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.89 | 0.9% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $27.72 | 0.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.88 | 0.8% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $25.96 | 0.8% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $22.04 | 0.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.91 | 0.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.70 | 0.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.27 | 0.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.12 | 0.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.64 | 0.4% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $14.21 | 0.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $13.59 | 0.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $13.53 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,342.01 | 222 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $334.90 | 22 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $276.35 | 21 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $261.52 | 19 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $234.72 | 10 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $178.14 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $172.37 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $151.54 | 10 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $141.01 | 9 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $137.11 | 19 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $135.97 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $132.15 | 13 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $131.58 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $117.94 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $116.79 | 7 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $93.14 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $93.14 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $93.14 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $85.08 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $85.02 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $81.02 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $78.07 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $78.07 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $72.30 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $67.56 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $64.12 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $63.22 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $59.27 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.24 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $56.96 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $54.56 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $52.13 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $47.99 | 3 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $43.14 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $38.97 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $34.77 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $32.48 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.89 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $27.72 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $26.88 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $25.96 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.21 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $10.27 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $9.17 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $8.72 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 153 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 477 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 49 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 140 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 204 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 55 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 126 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 137 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
213 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
204 | 42 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
477 | 71 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
145 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
204 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
126 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
137 | 19 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
137 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
153 | 153 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
477 | 71 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
140 | 18 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1054 | 197 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1027 | 213 |
| Levothyroxine Sodium | Levothyroxine Sodium | 876 | 184 |
| Furosemide | Furosemide | 810 | 168 |
| Omeprazole | Omeprazole | 808 | 190 |
| Donepezil Hcl | Donepezil Hcl | 729 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 655 | 152 |
| Gabapentin | Gabapentin | 580 | 115 |
| Memantine Hcl | Memantine Hcl | 576 | 101 |
| Lisinopril | Lisinopril | 568 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 523 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 499 | 130 |
| Eliquis | Apixaban | 477 | 71 |
| Sertraline Hcl | Sertraline Hcl | 462 | 75 |
| Losartan Potassium | Losartan Potassium | 456 | 115 |
| Metoprolol Tartrate | Metoprolol Tartrate | 415 | 79 |
| Carvedilol | Carvedilol | 401 | 91 |
| Escitalopram Oxalate | Escitalopram Oxalate | 401 | 88 |
| Potassium Chloride | Potassium Chloride | 401 | 88 |
| Metformin Hcl | Metformin Hcl | 373 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 354 | 95 |
| Famotidine | Famotidine | 326 | 48 |
| Montelukast Sodium | Montelukast Sodium | 323 | 67 |
| Trazodone Hcl | Trazodone Hcl | 293 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 287 | 86 |
| Allopurinol | Allopurinol | 276 | 66 |
| Alprazolam | Alprazolam | 275 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 258 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 253 | 97 |
| Buspirone Hcl | Buspirone Hcl | 253 | 67 |
| Meloxicam | Meloxicam | 244 | 65 |
| Simvastatin | Simvastatin | 242 | 59 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 236 | 73 |
| Spironolactone | Spironolactone | 235 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 234 | 46 |
| Lorazepam | Lorazepam | 232 | 51 |
| Farxiga | Dapagliflozin Propanediol | 213 | 39 |
| Metformin Hcl Er | Metformin Hcl | 213 | 57 |
| Tramadol Hcl | Tramadol Hcl | 213 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 208 | 40 |
| Azithromycin | Azithromycin | 207 | 154 |
| Jardiance | Empagliflozin | 204 | 42 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 198 | 23 |
| Prednisone | Prednisone | 196 | 101 |
| Fluoxetine Hcl | Fluoxetine Hcl | 185 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 170 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 168 | 37 |
| Levetiracetam | Levetiracetam | 165 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 161 | 33 |
| Atenolol | Atenolol | 156 | 41 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 153 | 153 |
| Finasteride | Finasteride | 153 | 30 |
| Mirtazapine | Mirtazapine | 152 | 29 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 148 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 145 | 33 |
| Xarelto | Rivaroxaban | 145 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 143 | 23 |
| Baclofen | Baclofen | 142 | 14 |
| Gemtesa | Vibegron | 140 | 18 |
| Celecoxib | Celecoxib | 138 | 36 |
| Bupropion Xl | Bupropion Hcl | 137 | 36 |
| Rexulti | Brexpiprazole | 137 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 129 | 26 |
| Mounjaro | Tirzepatide | 126 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 124 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 121 | 22 |
| Januvia | Sitagliptin Phosphate | 119 | 20 |
| Ozempic | Semaglutide | 119 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 117 | 21 |
| Tradjenta | Linagliptin | 115 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 114 | 35 |
| Ezetimibe | Ezetimibe | 110 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 109 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 109 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 34 |
| Pregabalin | Pregabalin | 99 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 98 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 19 |
| Topiramate | Topiramate | 93 | suppressed |
| Myrbetriq | Mirabegron | 92 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 91 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 90 | 76 |
| Dicyclomine Hcl | Dicyclomine Hcl | 90 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 90 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 89 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 88 | 68 |
| Clonazepam | Clonazepam | 87 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 52 |
| Valsartan | Valsartan | 84 | 28 |
| Aripiprazole | Aripiprazole | 83 | suppressed |
| Synthroid | Levothyroxine Sodium | 83 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 81 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 80 | 25 |
| Divalproex Sodium | Divalproex Sodium | 80 | 12 |
| Clonidine Hcl | Clonidine Hcl | 79 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 44 |
| Chlorthalidone | Chlorthalidone | 76 | 15 |
| Lamotrigine | Lamotrigine | 75 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 73 | 25 |
| Methimazole | Methimazole | 73 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 72 | 60 |
| Eszopiclone | Eszopiclone | 72 | 16 |
| Propranolol Hcl | Propranolol Hcl | 68 | 18 |
| Repatha Sureclick | Evolocumab | 68 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 17 |
| Glimepiride | Glimepiride | 67 | 17 |
| Naproxen | Naproxen | 67 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 67 | 16 |
| Olanzapine | Olanzapine | 66 | 16 |
| Fluconazole | Fluconazole | 65 | 48 |
| Methylprednisolone | Methylprednisolone | 65 | 49 |
| Lovastatin | Lovastatin | 63 | 14 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 62 | 61 |
| Metoclopramide Hcl | Metoclopramide Hcl | 62 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 61 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 61 | 14 |
| Cephalexin | Cephalexin | 59 | 42 |
| Novolog Flexpen | Insulin Aspart | 59 | 24 |
| Nitroglycerin | Nitroglycerin | 58 | 34 |
| Anastrozole | Anastrozole | 56 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 56 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 56 | suppressed |
| Kerendia | Finerenone | 55 | suppressed |
| Linzess | Linaclotide | 55 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 54 | 12 |
| Latanoprost | Latanoprost | 54 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 52 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 51 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 12 |
| Risperidone | Risperidone | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 51 | 13 |
| Dutasteride | Dutasteride | 50 | 19 |
| Entresto | Sacubitril/Valsartan | 49 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 11 |
| Colchicine | Colchicine | 47 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 23 |
| Midodrine Hcl | Midodrine Hcl | 47 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 47 | 13 |
| Torsemide | Torsemide | 47 | 11 |
| Galantamine Hbr | Galantamine Hbr | 46 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 46 | suppressed |
| Mupirocin | Mupirocin | 45 | 34 |
| Carbamazepine | Carbamazepine | 43 | suppressed |
| Estradiol | Estradiol | 43 | 13 |
| Glipizide | Glipizide | 43 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 42 | suppressed |
| Fenofibrate | Fenofibrate | 42 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | suppressed |
| Bumetanide | Bumetanide | 40 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | suppressed |
| Diazepam | Diazepam | 40 | 14 |
| Nystatin | Nystatin | 40 | 29 |
| Amoxicillin | Amoxicillin | 39 | 35 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 11 |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Verquvo | Vericiguat | 37 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 36 | suppressed |
| Metronidazole | Metronidazole | 36 | 29 |
| Calcitriol | Calcitriol | 35 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | 13 |
| Rivastigmine | Rivastigmine | 35 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 32 | suppressed |
| Levemir Flexpen | Insulin Detemir | 32 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 15 |
| Ramipril | Ramipril | 30 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | 13 |
| Cefdinir | Cefdinir | 27 | 24 |
| Ondansetron Odt | Ondansetron | 27 | 13 |
| Temazepam | Temazepam | 27 | suppressed |
| Amantadine | Amantadine Hcl | 26 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 26 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | 14 |
| Klor-Con M20 | Potassium Chloride | 26 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 25 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Cimetidine | Cimetidine | 25 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 21 |
| Mesalamine | Mesalamine | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 25 | suppressed |
| Belsomra | Suvorexant | 24 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 23 | 21 |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Progesterone | Progesterone, Micronized | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 23 | suppressed |
| Calcipotriene | Calcipotriene | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | 15 |
| Ssd | Silver Sulfadiazine | 22 | 12 |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | 12 |
| Lidocaine Hcl | Lidocaine Hcl | 21 | 15 |
| Minocycline Hcl | Minocycline Hcl | 21 | suppressed |
| Modafinil | Modafinil | 21 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 20 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 20 | 11 |
| Acetazolamide | Acetazolamide | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 11 |
| Acyclovir | Acyclovir | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 17 |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Admelog Solostar | Insulin Lispro | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Perphenazine | Perphenazine | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 12 |
| Silodosin | Silodosin | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Rhopressa | Netarsudil Mesylate | 11 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 11 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,342.01 · 222 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, Auvelity, Azstarys, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, FANAPT, GARDASIL 9, GEMTESA, HETLIOZ, IBSRELA, INGREZZA, INSPIRE, JARDIANCE, JOURNAVX, KISUNLA, Kerendia, LEQVIO, LINZESS, LYBALVI, Leqembi, MINIMED 780G, MOUNJARO, MYFEMBREE, NURTEC ODT, OTEZLA, Ohtuvayre, Omnipod, Ozempic, PREVNAR 20, PROLIA, QULIPTA, Qelbree, REPATHA, REXULTI, Rybelsus, SPRAVATO, Sunosi, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VAXELIS, VERQUVO, VOQUEZNA, VRAYLAR, VYEPTI, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 27 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error